Cellectar
CLRB
Cellectar (CLRB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ladenburg Thalmann | Initiated Coverage | Buy | $10.00 | May 15, 2026 |
| Maxim Group | Upgraded | Hold → Buy | $10.00 | Mar 10, 2026 |
| Maxim Group | Downgraded | Buy → Hold | — | May 14, 2025 |
| Oppenheimer | Downgraded | Outperform → Perform | — | Dec 11, 2024 |
| Oppenheimer | Maintained | Outperform | $12.00 from $14.00 | Nov 19, 2024 |
| Oppenheimer | Maintained | Outperform | $14.00 | Oct 11, 2024 |
| Oppenheimer | Maintained | Outperform | $12.00 from $11.00 | Mar 28, 2024 |
| Roth MKM | Maintained | Buy | $28.00 from $20.00 | Mar 28, 2024 |
| Roth MKM | Maintained | Buy | $20.00 | Mar 4, 2024 |
Frequently asked questions
What is the latest analyst rating on CLRB?
On May 15, 2026, Ladenburg Thalmann initiated coverage of Cellectar at Buy with a price target of $10.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.